SCHEMBL20913872

SCHEMBL20913872

CC(C)(C)OC(=O)N1CCCC(F)(CCN)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.40
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GRIN2B Q13224 1/20 0.37
GRIN2C Q14957 1/20 0.37
USP30 Q70CQ3 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 2/20 0.37
ALDH1A1 P00352 1/20 0.37
DPP4 P27487 1/20 0.36
PIK3R1 P27986 2/20 0.35
PIK3CA P42336 2/20 0.35
CTSK P43235 1/20 0.35
EPHX1 P07099 1/20 0.35
MMP2 P08253 1/20 0.35
MMP13 P45452 1/20 0.35
MMP14 P50281 1/20 0.35
ADAM17 P78536 1/20 0.35
HDAC2 Q92769 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19448354 1.00 HPGD (0.40) HPGDUSP2SMN1; SMN2GRIN2BGRIN2C
SCHEMBL18688893 0.93 HPGD (0.37) HPGDUSP2SMN1; SMN2GRIN2BGRIN2C
SCHEMBL18689518 0.93 HPGD (0.37) HPGDUSP2SMN1; SMN2GRIN2BGRIN2C
SCHEMBL14242637 0.90 HPGD (0.40) HPGDUSP2SMN1; SMN2GRIN2BGRIN2C
SCHEMBL12180144 0.90 HPGD (0.40) HPGDUSP2SMN1; SMN2GRIN2BGRIN2C
SCHEMBL19448348 0.89 HPGD (0.40) HPGDUSP2SMN1; SMN2USP30MEN1
SCHEMBL19437430 0.86 HPGD (0.38) HPGDUSP2SMN1; SMN2USP30MEN1
SCHEMBL19448351 0.86 HPGD (0.38) HPGDUSP2SMN1; SMN2USP30MEN1
SCHEMBL19437429 0.86 HPGD (0.38) HPGDUSP2SMN1; SMN2USP30MEN1
SCHEMBL18688892 0.86 HPGD (0.38) HPGDUSP2SMN1; SMN2USP30MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108884083-B Benzo [ B ] furans as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2022-02-25 CN disclosed
CN-108884070-B Pyridyl derivatives as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2021-07-02 CN disclosed
US-10934272-B2 Pyridyl derivatives as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2021-03-02 US disclosed
EP-3440069-B1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2020-10-28 EP disclosed
US-10583112-B2 Benzo[b]furans as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2020-03-10 US disclosed
EP-3440075-B1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2020-01-29 EP disclosed
US-20190151279-A1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-05-23 US disclosed
US-20190119248-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934272-B2 Pyridyl derivatives as bromodomain inhibitors BRD4, BRD3, BRDT HPGD 214/4885USP2 2873/4885SMN1; SMN2 3654/4885
US-10583112-B2 Benzo[b]furans as bromodomain inhibitors BRD4, BRD3, BRD2 HPGD 234/4885USP2 1891/4885SMN1; SMN2 3232/4885
US-20190119248-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRDT HPGD 214/4885USP2 2873/4885SMN1; SMN2 3654/4885
US-20190151279-A1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD2 HPGD 234/4885USP2 1891/4885SMN1; SMN2 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.